

National Health and Medical Research Council

Entity resources and planned performance

National Health and Medical Research Council

Section 1: Entity overview and resources	378
1.1 Strategic direction statement.....	378
1.2 Entity resource statement.....	379
1.3 Budget measures	381
Section 2: Outcomes and planned performance	382
2.1 Budgeted expenses and performance for Outcome 1	382
Section 3: Budgeted financial statements.....	388
3.1 Budgeted financial statements	388
3.2. Budgeted financial statements tables.....	389

National Health and Medical Research Council

Section 1: Entity overview and resources

1.1 Strategic direction statement¹

The National Health and Medical Research Council (NHMRC) is the Australian Government's key entity for managing investment in health and medical research. NHMRC is also responsible for developing evidence-based health advice for the Australian community, health professionals and governments, and for promoting the highest standards of ethics and integrity in health and medical research.

NHMRC continues to support high quality research through its grant program, which encourages innovation in research and provides opportunities for talented researchers at all career stages. This work is facilitated by NHMRC's modern grants management solution, Sapphire, which has streamlined the application, peer review assessment and grant management processes.

NHMRC continues to support the Department of Health and Aged Care with the delivery of the Medical Research Future Fund (MRFF) grant opportunities. NHMRC and the Department are also progressing work to improve alignment and coordination between the MRFF and NHMRC's grant program, delivered through the Medical Research Endowment Account (MREA), as well as commencing work together towards the Department's delivery of a National Strategy for Health and Medical Research.

NHMRC's work also facilitates and promotes the translation of evidence from health and medical research into practices, policies and products designed to prevent and treat illness and improve the health of the Australian community. NHMRC's guidelines and advice support states and territories in achieving consistent standards in public and environmental health.

The role and functions of NHMRC are set out in the *National Health and Medical Research Council Act 1992*. NHMRC also has statutory obligations under the *Prohibition of Human Cloning for Reproduction Act 2002*, the *Research Involving Human Embryos Act 2002*, and the *Medical Research Future Fund Act 2015*. NHMRC is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

¹ For more information about the strategic direction of the NHMRC, refer to the current Corporate Plan, available at: www.nhmrc.gov.au/about-us/corporate-plans-and-annual-reports

1.2 Entity resource statement

Table 1.1 shows the total resourcing from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity's operations) classification.

For more detailed information on special accounts and special appropriations, please refer to the *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the 'Budgeted expenses by Outcome 1' tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis. Amounts presented below are consistent with amounts presented in the Appropriation Bills themselves.

Table 1.1: NHMRC resource statement – Budget estimates for 2025–26 as at Budget March 2025

	2024–25 Estimated actual \$'000	2025–26 Estimate \$'000
DEPARTMENTAL		
Prior year appropriation available	5,346	5,346
Annual appropriations		
Ordinary annual services ^(a)		
Departmental appropriation	38,248	45,964
s74 retained revenue receipts ^(b)	19,720	5,974
Departmental Capital Budget ^(c)	190	192
Other services ^(d)		
Equity injection	-	-
Total departmental annual appropriations	58,158	52,130
Total departmental resourcing for NHMRC	63,504	57,476

Table 1.1: NHMRC resource statement – Budget estimates for 2025–26 as at Budget March 2025 (continued)

	2024–25 Estimated actual \$'000	2025–26 Estimate \$'000
ADMINISTERED		
Annual appropriations		
Ordinary annual services ^(a)		
Outcome 1	953,872	973,172
Other services ^(d)		
Administered assets and liabilities	-	-
Total administered annual appropriations	953,872	973,172
Special accounts ^(e)		
Opening balance	366,410	332,585
Appropriation receipts	940,330	959,206
Appropriation receipts - other entities ^(f)	-	-
Non-appropriation receipts	10,000	10,000
Total special accounts	1,316,740	1,301,791
Total administered resourcing	2,270,612	2,274,963
Less appropriations drawn from annual or special appropriations above and credited to special accounts ^(g)	(940,330)	(959,206)
Total administered resourcing	1,330,282	1,315,757
Total resourcing for NHMRC	1,393,786	1,373,233
	2024–25	2025–26
Average staffing level (number)	205	205

All figures are GST exclusive.

^(a) Appropriation Bill (No. 1) 2025–2026 and Supply Bill (No. 1) 2025–2026.

^(b) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

^(c) Departmental Capital Budgets are not separately identified in Appropriation Bill (No.1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

^(d) Appropriation Bill (No. 2) 2025–2026 and Supply Bill (No. 2) 2025–2026.

^(e) For further information on special appropriations and special accounts, please refer to Budget Paper No. 4 - Agency Resourcing. Also see Table 2.1 within this chapter for further information on outcome and program expenses broken down by various funding sources, e.g. annual appropriations, special appropriations and special accounts.

^(f) Appropriation receipts from the Department of Health and Aged Care.

^(g) Appropriation receipts included above.

1.3 Budget measures

Budget measures in Part 1 relating to the NHMRC are detailed in the Budget Paper No. 2 and are summarised below.

Table 1.2: NHMRC 2025–26 Budget measures

Part 1: Measures announced since the 2024–25 Mid-Year Economic and Fiscal Outlook (MYEFO)

Program	2024–25 \$'000	2025–26 \$'000	2026–27 \$'000	2027–28 \$'000	2028–29 \$'000
Medical Research and Clinical Trials^(a)					
National Health and Medical Research Council					
Departmental payments	1.1	7,764	-	-	-
Total payments		7,764	-	-	-
Savings from External Labour - further extension^(a)					
National Health and Medical Research Council					
Departmental payments	1.1	-	-	-	(827)
Total payments		-	-	-	(827)

Prepared on a Government Financial Statistics (Underlying Cash) basis. Figures displayed as a negative (-) represent a decrease in funds and a positive (+) represent an increase in funds.

^(a) NHMRC is not the lead entity for this measure. NHMRC impacts only are shown in this table.

Section 2: Outcomes and planned performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth performance framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measure described in Portfolio Budget Statements will be read with broader information provided in an entity's corporate plans and annual performance statements – included in Annual Reports – to provide a complete picture of an entity's planned and actual performance.

The most recent Corporate Plan and Annual Performance Statements for the NHMRC can be found at: www.nhmrc.gov.au/about-us/corporate-plans-and-annual-reports

2.1 Budgeted expenses and performance for Outcome 1

Outcome 1

Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health.

Program contributing to Outcome 1

Program 1.1: Health and Medical Research

Linked programs

Other Commonwealth entities that contribute to Outcome 1
Department of Health and Aged Care
Program 1.1: Health Research, Coordination and Access
Program 1.8: Health Protection, Emergency Response and Regulation
The Department of Health and Aged Care contributes to health and medical research through the Medical Research Future Fund, which will support the sustainability of the health system into the future, and drive further medical innovation (1.1).
The Department of Health and Aged Care contributes to the promotion of public health through the Chief Medical Officer and the Office of Health Protection and Response, which coordinates national health protection policy and response (1.8).

Budgeted expenses for Outcome 1

This table shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by Administered and Departmental funding sources.

Table 2.1.1: Budgeted expenses for Outcome 1

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
Program 1.1: Health and Medical Research					
Administered expenses					
Ordinary annual services ^(a) to Medical Research Endowment Account	953,872 (940,330)	973,172 (959,206)	993,978 (979,761)	1,013,856 (999,344)	1,036,158 (1,021,329)
Special accounts					
Medical Research Endowment Account	984,155	999,615	999,784	1,030,241	1,119,088
Departmental expenses					
Departmental appropriation ^(b)	56,270	49,172	49,942	49,536	49,399
Expenses not requiring appropriation in the Budget year ^(c)	5,760	5,796	5,733	5,622	5,773
Operating deficit (surplus)	(3,962)	(2,930)	(2,715)	(2,482)	(2,815)
Total for Program 1.1	1,055,765	1,065,619	1,066,961	1,097,429	1,186,274
Total expenses for Outcome 1	1,055,765	1,065,619	1,066,961	1,097,429	1,186,274

	2024–25	2025–26
Average staffing level (number)	205	205

(a) Appropriation Bill (No. 1) 2025–2026 and Supply Bill (No. 1) 2025–2026.

(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No. 1), Supply Bill (No. 1)' and 'Revenue from independent sources (s74)'.
(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

Performance measures for Outcome 1

Table 2.1.2 details the performance measures for each program associated with Outcome 1. It is used by entities to describe the results they plan to achieve and the related key activities, as detailed in the current corporate plan, the context in which these activities are delivered, and how the performance of these activities will be measured. Where relevant, details of the 2025–26 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance measures for Outcome 1

<p>Outcome 1</p> <p>Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health.</p>	
<p>Program 1.1: Health and Medical Research</p> <p>The Australian Government, through NHMRC, aims to:</p> <ul style="list-style-type: none"> • create knowledge and build research capability through investment in the highest quality health and medical research, and the best researchers (Investment) • drive the translation of health and medical research into public policy, health systems and clinical practice, and support the commercialisation of research discoveries (Translation) • maintain a strong integrity framework underpinning rigorous and ethical research promoting community trust (Integrity). 	
<p>Key Activities</p>	<ul style="list-style-type: none"> • Deliver funding schemes that invest in the best researchers and research to meet Australia’s diverse health and medical research needs and invest in innovative and collaborative research projects (Investment) • Develop and update guidelines in public, clinical and environmental health to support consistent standards, promote prevention and public health and inform clinical, policy and regulatory decision (Translation) • Promote best-practice evidence review and standards, including support for rapidly updated and living guidelines, Guidelines for Guidelines and approval of third-party public health and clinical practice guidelines (Translation) • Maintain national standards, codes and guidelines that promote best practice in research governance and ethics review processes and provide guidance on ethical issues in health (Integrity) • Promote research integrity, including maintaining the Australian Code for the Responsible Conduct of Research and other guidance, and supporting the work of the Australian Research Integrity Committee (Integrity).

Program 1.1: Health and Medical Research		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Research grants in basic science, clinical medicine, public health and health services research meet the health needs of Australians, and include national, state and territory and community priorities.	Grants were awarded based on expert peer review across the full spectrum of health and medical research areas, and focus on achieving better health outcomes. ² On track More than 5% of NHMRC's annual research grant budget was expended and awarded to research that will provide better health outcomes for Aboriginal and Torres Strait Islander people. On track
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	As per 2024–25.	Grants are awarded based on expert peer review across the full spectrum of health and medical research areas, and focus on achieving better health outcomes. ³ More than 5% of NHMRC's annual research grant budget is awarded to research that will provide better health outcomes for Aboriginal and Torres Strait Islander people. ⁴
Forward Estimates 2026–29	As per 2025–26.	As per 2025–26.

² Further details, including a breakdown of research funding awarded, will be published in the NHMRC Annual Report 2024–25.

³ This target assesses the distribution of NHMRC grant expenditure and of new grants awarded.

⁴ This performance target was modified in NHMRC's Corporate Plan 2024–25 to focus on new grants awarded only (previously the target included expenditure on all active grants, as well as new grants awarded).

Program 1.1: Health and Medical Research		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Support an Australian health system that is research-led, evidence-based, efficient and sustainable.	<p>NHMRC has developed and/or is developing the following clinical practice, public and environmental health guidelines:</p> <ul style="list-style-type: none"> • Review of 2013 Australian Dietary Guidelines (in progress) • Clinical Practice Guidelines for Myalgic Encephalomyelitis /Chronic Fatigue Syndrome, Long COVID and Related Conditions (in progress) • Evidence evaluations of 16 natural therapies excluded from private health insurance rebates on 1 April 2019 (completed January 2025) • Nutrient Reference Values (NRVs) for Australia and New Zealand – priority rolling review 2006 NRVs (Sodium, Iodine and Selenium in progress) • Australian Drinking Water Guidelines – consequential edits resulting from publication of microbial health-based targets (published in December 2024) • Australian drinking water guidelines: public health advice for lead substitutes in plumbing products (on track for publication in 2024–25) • Australian Drinking Water Guidelines: review of existing PFAS guideline values (on track for publication in 2024–25) • Review of Guidelines for Managing Risks from Recreational Water (in progress) • Review of Guidelines for Guidelines (in progress) • Review of Procedures and Requirements for meeting the NHMRC Standards for Clinical Practice Guidelines (in progress). <p>On track NHMRC has approved, or expects to approve, the following clinical practice guidelines by third parties:</p> <ul style="list-style-type: none"> • Australian Postnatal Care Guidelines • Australian Guidelines for Assessment and Diagnosis of Fetal Alcohol Spectrum Disorder • Clinical Practice Guidelines for the Management of Overweight and Obesity for Adults, Adolescents and Children in Australia • The Implementation of Newborn

		<p>Screening for Spinal Muscular Atrophy in Australia and New Zealand</p> <ul style="list-style-type: none"> • Updates to the Australian Pregnancy Care Guidelines • Updates to An Australian Living Guideline for the Pharmaceutical Management of Inflammatory Arthritis • Updates to Australian and New Zealand Living Clinical Guidelines for Stroke Management • Updates to the Australian Immunisation Handbook (Zoster and Respiratory Syncytial Virus chapters). <p>On track</p>
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	As per 2024–25.	Develop and/or approve public and environmental health and clinical practice guidelines.
Forward Estimates 2026–29	As per 2025–26.	As per 2025–26.

Program 1.1: Health and Medical Research		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Research is conducted responsibly, ethically and with integrity in Australia.	<p>Research integrity matters were managed appropriately by administering institutions in line with the requirements of the <i>Australian Code for the Responsible Conduct of Research</i>.⁵</p> <p>On track</p>
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	As per 2024–25.	Research integrity matters are managed appropriately by administering institutions in line with the requirements of the <i>Australian Code for the Responsible Conduct of Research</i> .
Forward Estimates 2026–29	As per 2025–26.	As per 2025–26.
Material changes to Program 1.1 resulting from 2025–26 Budget Measures: Nil		

⁵ Details, including the results of the 2024 Institutional Annual Compliance Report (not yet available) and reviews by the Australian Research Integrity Committee, will be published in the NHMRC Annual Report 2024–25.

Section 3: Budgeted financial statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2025–26 Budget year, including the impact of budget measures and resourcing on financial statements.

3.1 Budgeted financial statements

3.1.1 Differences between entity resourcing and financial statements

The NHMRC provides assistance for the medical research through the Medical Research Endowment Account (MREA) special account established under the *National Health and Medical research Council Act 1992* (NHMRC Act). The purpose of the MREA is outlined in section 51 of the NHMRC Act.

Table 3.1.1: Estimates of Special Account Cash Flows and Balances

		Opening balance 2025–26 2024–25 Outcome	Other receipts 2025–26 2024–25	Appropriation receipts 2025–26 2024–25	Payments 2025–26 2024–25	Closing balance 2025–26 2024–25
		\$'000	\$'000	\$'000	\$'000	\$'000
Medical Research Endowment Account	1	332,585 366,410	10,000 10,000	959,206 940,330	999,615 984,155	302,176 332,585
Total Special Accounts						
2025–26 estimate		332,585	10,000	959,206	999,615	302,176
2024–25 estimated actual		366,410	10,000	940,330	984,155	332,585

3.1.2 Explanatory notes and analysis of budgeted financial statements

Departmental Resources

Comprehensive Income Statement (showing net cost of services)

Revenue and expenditure for 2025–26 is expected to be in line with Government forecasts, with employee expenses to be 53% of total expenditure.

Balance Sheet

Assets and Liabilities are expected to remain stable across the Budget and forward years.

Administered Resources

The Administered accounts are used as a mechanism to transfer the majority of funds to NHMRC's Special Account (Medical Research Endowment Account). In 2025–26 the transfer to the Special Account is expected to be \$959 million.

3.2. Budgeted financial statements tables**Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June**

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
EXPENSES					
Employee benefits	32,747	35,147	35,146	36,271	37,431
Supplier expenses	23,282	13,802	14,617	13,124	11,564
Depreciation and amortisation	5,860	5,896	5,833	5,722	5,873
Interest on RoU	141	123	79	41	304
Total expenses	62,030	54,968	55,675	55,158	55,172
LESS:					
OWN-SOURCE INCOME					
Revenue					
Sale of goods and rendering of services	12,847	12,847	12,847	12,847	12,847
Total revenue	12,847	12,847	12,847	12,847	12,847
Gains					
Other	100	100	100	100	100
Total gains	100	100	100	100	100
Total own-source income	12,947	12,947	12,947	12,947	12,947
Net cost of (contribution by) services	49,083	42,021	42,728	42,211	42,225
Revenue from Government	45,121	39,091	40,013	39,729	39,410
Surplus (deficit)	(3,962)	(2,930)	(2,715)	(2,482)	(2,815)
Surplus (deficit) attributable to the Australian Government	(3,962)	(2,930)	(2,715)	(2,482)	(2,815)
OTHER COMPREHENSIVE INCOME					
Changes in asset revaluation reserves	-	-	-	-	-
Total other comprehensive income (loss)	-	-	-	-	-
Total comprehensive income (loss) attributable to the Australian Government	(3,962)	(2,930)	(2,715)	(2,482)	(2,815)

Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June (continued)

Note: Impact of net cash appropriation arrangements

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
Total comprehensive income (loss) attributable to the Australian Government	(3,962)	(2,930)	(2,715)	(2,482)	(2,815)
plus: non-appropriated expenses depreciation/amortisation expenses	3,069	3,046	2,978	2,836	2,601
plus: depreciation/amortisation expenses for RoU assets	2,791	2,850	2,855	2,886	3,272
less: lease principal repayments	(2,789)	(2,966)	(3,118)	(3,240)	(3,058)
Total comprehensive income (loss) attributable to the agency	(891)	-	-	-	-

Prepared on Australian Accounting Standards basis.

RoU = Right-of-Use asset

Table 3.2: Budgeted departmental balance sheet (as at 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
ASSETS					
Financial assets					
Cash and cash equivalents	1,705	1,705	1,705	1,705	1,705
Receivables	11,246	4,373	4,373	4,373	4,373
Total financial assets	12,951	6,078	6,078	6,078	6,078
Non-financial assets					
Property, plant and equipment	2,111	1,703	1,366	1,171	1,216
Land and buildings	8,088	6,167	3,312	647	13,797
Intangibles	18,949	16,503	14,057	11,611	9,165
Other	863	863	863	863	863
Total non-financial assets	30,011	25,236	19,598	14,292	25,041
Total assets	42,962	31,314	25,676	20,370	31,119
LIABILITIES					
Payables					
Suppliers	1,583	1,583	1,583	1,583	1,583
Other payables	10,471	3,598	3,598	3,598	3,598
Total payables	12,054	5,181	5,181	5,181	5,181
Interest bearing liabilities					
Leases	9,126	7,089	3,971	952	14,316
Total interest bearing liabilities	9,126	7,089	3,971	952	14,316
Provisions					
Employees	7,744	7,744	7,744	7,744	7,744
Total provisions	7,744	7,744	7,744	7,744	7,744
Total liabilities	28,924	20,014	16,896	13,877	27,241
Net Assets	14,038	11,300	8,780	6,493	3,878
EQUITY					
Contributed equity	17,576	17,768	17,963	18,158	18,358
Reserves	1,367	1,367	1,367	1,367	1,367
Retained surpluses or (accumulated deficits)	(4,905)	(7,835)	(10,550)	(13,032)	(15,847)
Total equity	14,038	11,300	8,780	6,493	3,878

Prepared on Australian Accounting Standards basis.

Table 3.3: Departmental statement of changes in equity – summary of movement (Budget year 2025–26)

	Retained earnings	Asset revaluation reserve	Contributed equity/ capital	Total equity
	\$'000	\$'000	\$'000	\$'000
Opening balance as at 1 July 2025				
Balance carried forward from previous period	(4,905)	1,367	17,576	14,038
Surplus (deficit) for the period	(2,930)	-	-	(2,930)
Capital budget - Bill 1 (DCB)	-	-	192	192
Estimated closing balance as at 30 June 2026	(7,835)	1,367	17,768	11,300

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

Table 3.4: Budgeted departmental statement of cash flows (for the period ended 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Goods and services	12,847	12,847	12,847	12,847	12,847
Appropriations	45,121	39,091	40,013	39,729	39,410
Net GST received	-	-	-	-	-
Total cash received	57,968	51,938	52,860	52,576	52,257
Cash used					
Employees	32,747	35,147	35,146	36,271	37,431
Suppliers	22,291	13,702	14,517	13,024	11,464
Interest payments on lease liability	141	123	79	41	304
Total cash used	55,179	48,972	49,742	49,336	49,199
Net cash from (or used by) operating activities	2,789	2,966	3,118	3,240	3,058
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and equipment	190	192	195	195	200
Total cash used	190	192	195	195	200
Net cash from (or used by) investing activities	(190)	(192)	(195)	(195)	(200)
FINANCING ACTIVITIES					
Cash received					
Equity injections - Bill 2	-	-	-	-	-
Capital budget - Bill 1 (DCB)	190	192	195	195	200
Total cash received	190	192	195	195	200
Cash used					
Lease principal repayments	2,789	2,966	3,118	3,240	3,058
Total cash used	2,789	2,966	3,118	3,240	3,058
Net cash from (or used by) financing activities	(2,599)	(2,774)	(2,923)	(3,045)	(2,858)
Net increase (or decrease) in cash held	-	-	-	-	-
Cash and cash equivalents at the beginning of the reporting period	1,705	1,705	1,705	1,705	1,705
Cash and cash equivalents at the end of the reporting period	1,705	1,705	1,705	1,705	1,705

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

Table 3.5: Departmental capital budget statement (for the period ended 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
CAPITAL APPROPRIATIONS					
Capital budget - Bill 1 (DCB)	190	192	195	195	200
Equity injections - Bill 2	-	-	-	-	-
Total capital appropriations	190	192	195	195	200
Total new capital appropriations represented by:					
Purchase of non-financial assets	190	192	195	195	200
Total items	190	192	195	195	200
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriations - equity injection ^(a)	-	-	-	-	-
Funded by capital appropriation - DCB ^(b)	190	192	195	195	200
Funded internally from departmental resources	-	-	-	-	-
Total acquisitions of non-financial assets	190	192	195	195	200
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	190	192	195	195	200
Total cash used to acquire assets	190	192	195	195	200

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

^(a) Includes both current Appropriation Bill (No. 2), Supply Bill (No. 2) and prior Appropriation Act (No. 2/4/6) appropriations.

^(b) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.6: Statement of departmental asset movements (Budget year 2025–26)

	Buildings	Property, plant and equipment	Intangibles	Total
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2025				
Gross book value	-	5,534	36,038	41,572
Gross book value - RoU	23,431	707	-	24,138
Accumulated depreciation/ amortisation and impairment	-	(3,417)	(17,089)	(20,506)
Accumulated depreciation/amortisation and impairment - RoU	(15,343)	(713)	-	(16,056)
Opening net book balance	8,088	2,111	18,949	29,148
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
By purchase - appropriation ordinary annual services	-	192	-	192
By purchase - RoU	-	-	-	-
Total additions	-	192	-	192
Other movements				
Depreciation/amortisation expense	-	(600)	(2,446)	(3,046)
Depreciation/amortisation expense - RoU	(2,850)	-	-	(2,850)
Other movements	929	-	-	929
Total other movements	(1,921)	(600)	(2,446)	(4,967)
As at 30 June 2026				
Gross book value	-	5,726	36,038	41,764
Gross book value - RoU	23,431	707	-	24,138
Accumulated depreciation/amortisation and impairment	-	(4,017)	(19,535)	(23,552)
Accumulated depreciation/amortisation and impairment - RoU	(17,264)	(713)	-	(17,977)
Closing net book balance	6,167	1,703	16,503	24,373

Prepared on Australian Accounting Standards basis.

RoU = Right-of-Use Asset

Table 3.7: Schedule of budgeted income and expenses administered on behalf of Government (for the period ended 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT					
Grants – MREA	984,155	999,615	999,784	1,030,241	1,119,088
Suppliers	13,542	13,966	14,217	14,512	14,829
Total expenses administered on behalf of Government	997,697	1,013,581	1,014,001	1,044,753	1,133,917
REVENUES ADMINISTERED ON BEHALF OF GOVERNMENT					
Recoveries	5,000	5,000	5,000	5,000	5,000
Sales of goods and services	5,000	5,000	5,000	5,000	5,000
Total income administered on behalf of Government	10,000	10,000	10,000	10,000	10,000

Prepared on Australian Accounting Standards basis.

MREA = Medical Research Endowment Account

Table 3.8: Schedule of budgeted assets and liabilities administered on behalf of Government (as at 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT					
Financial assets					
Cash and cash equivalents	332,585	302,176	292,153	271,256	183,497
Receivables	5,386	5,386	5,386	5,386	5,386
Total financial assets	337,971	307,562	297,539	276,642	188,883
Total assets administered on behalf of Government	337,971	307,562	297,539	276,642	188,883
LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT					
Payables					
Grants	8,296	8,296	8,296	8,296	8,296
Suppliers	2,163	2,163	2,163	2,163	2,163
Other	294	294	294	294	294
Total payables	10,753	10,753	10,753	10,753	10,753
Total liabilities administered on behalf of Government	10,753	10,753	10,753	10,753	10,753

Prepared on Australian Accounting Standards basis.

Table 3.9: Schedule of budgeted administered cash flows (for the period ended 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Cash received – other	10,000	10,000	10,000	10,000	10,000
Net GST received	26,000	26,000	26,000	26,000	26,000
Total cash received	36,000	36,000	36,000	36,000	36,000
Cash used					
Grant payments	984,155	999,615	999,784	1,030,241	1,119,088
Suppliers	13,542	13,966	14,217	14,512	14,829
Net GST paid	26,000	26,000	26,000	26,000	26,000
Total cash used	1,023,697	1,039,581	1,040,001	1,070,753	1,159,917
Net cash from (or used by) operating activities	(987,697)	(1,003,581)	(1,004,001)	(1,034,753)	(1,123,917)
Net increase (or decrease) in cash held	(987,697)	(1,003,581)	(1,004,001)	(1,034,753)	(1,123,917)
Cash at beginning of reporting period	366,410	332,585	302,176	292,153	271,256
Cash from the OPA for:					
- appropriations	953,872	973,172	993,978	1,013,856	1,036,158
Cash at end of reporting period	332,585	302,176	292,153	271,256	183,497

Prepared on Australian Accounting Standards basis.

OPA = Official Public Account